Ardelyx Garners $30,000,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4848256e-111f-4a83-a7a3-e516ea34b77c&Preview=1 -
Date
8/31/2011 -
Company Name
Ardelyx -
Mailing Address
34175 Ardenwood Blvd. Fremont, CA 94555 -
Company Description
The company develops therapeutics for disease treatment. -
Website
http://www.ardelyx.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series B -
Proceeds Purposes
The proceeds of the financing will be used to advance Ardelyx’s pipeline that includes three product candidates: a clinical stage product, RDX5791, being evaluated in constipation-predominant irritable bowel syndrome (IBS-C) and in the prevention of excess dietary sodium absorption, and two preclinical products, RDX002 in chronic kidney disease and RDX009 in type 2 diabetes. -
M&A Terms
-
Venture Investor
New Enterprise Associates -
Venture Investor
CMEA Capital -
Venture Investor
Amgen Ventures
